This trial is evaluating whether Alpha Lipoic Acid 600 MG Oral Tablet will improve 2 primary outcomes and 6 secondary outcomes in patients with Apnea. Measurement will happen over the course of 8 weeks.
This trial requires 80 total participants across 2 different treatment groups
This trial involves 2 different treatments. Alpha Lipoic Acid 600 MG Oral Tablet is the primary treatment being studied. Participants will all receive the same treatment. Some patients will receive a placebo treatment. The treatments being tested are in Phase 2 & 3 and have had some early promising results.
"Approximately 1.5 million adults, mostly women, have obstructive sleep apnea while about 1.3 million have central sleep apnea. This data should help to inform practitioners of the importance of screening for sleep apnea as they are at higher risk of complications from sleep apnea, including cardio- and cerebrovascular accidents, and congestive heart failure." - Anonymous Online Contributor
"apnea may be the result of several underlying organic, neurological, or psychological mechanisms, all involving some abnormal functioning or structure of the brain. The most plausible theory is that apnea arises from insufficient neuronal discharge as a normal response to an acute change in oxygen concentration." - Anonymous Online Contributor
"When the cause of respiratory arrest is known, it is reasonable to proceed immediately for tracheal intubation, and proceed to resuscitation attempts. If CPR fails, then artificial ventilation must be instituted immediately to obtain appropriate oxygenation." - Anonymous Online Contributor
"All of these patients have apnea but they were not given the appropriate diagnostic evaluations for this disorder. In these patients, apnea is a disorder in which the patient was not monitored appropriately. This lack of monitoring can easily lead to the development of an apnoeic event and consequently death in the absence of appropriate treatment." - Anonymous Online Contributor
"There is poor evidence that adenotonsillectomy reduces the likelihood of the occurrence of apnoeic spells in children. Tonsillectomy did not alter the rates of subsequent adenoid growth when performed according to published guidelines for the surgery of children between 2 and 4 years of age." - Anonymous Online Contributor
"In neonatal intensive care unit patients, apnea has been seen in infants as young as 24 hours old. In this population, apnea signs can include a decrease in respiratory rate or oxygen saturation. In contrast to infants, apnea does not occur in healthy infants, and these infants are generally free of signs of apnea." - Anonymous Online Contributor
"Sleep-related respiratory disturbances may be primary in approximately one-third of children with sleep-related breathing disorders. The most common and predictable cause of apnea is an upper airway collapse during sleep and is not limited to the obstructive pathologies found in infants. The diagnosis of apnea in young children and treatment of apnea vary greatly from that of adults. Treatment of breathing abnormalities should therefore be taken into account in the management of each individual patient." - Anonymous Online Contributor
"The most common side effect of ALA is headache. The headache tends to resolve after the medication is stopped, and it is thought that it results from the drug's ability to scavenge reactive oxygen species (ROS). The second most common side-effect is constipation. It is recommended that if you are taking a patient medication with ALA that you do not take more than your daily dose of 1200 mg ALA at a time." - Anonymous Online Contributor
"The treatment of LA in patients diagnosed with T1-4N 0-1 M0 disease was well tolerated. It was shown that LA (600 mg/day) is ineffective for treatment for patients with lung-limited or head-and-neck cancer and for those who have not had successful treatment prior to the inclusion in the study. In the same study, the overall survival was prolonged by a median of 3 months. The most frequent toxicity was leukopenia, which occurred in 27 % of patients, but was generally mild. The most common site of toxicity was in the hematologic system, primarily leukopenia and thrombocytopaenia, which occurred in 14 % of patients." - Anonymous Online Contributor
"ALA 600 mg oral tablet is a well tolerated, well tolerated and effective treatment for MELAS syndrome. There is a need to determine the long term efficacy of the treatment." - Anonymous Online Contributor
"Most clinical Trialists have no information regarding the comorbidities of patients presenting to trials to be treated for [sleep apnea](https://www.withpower.com/clinical-trials/sleep-apnea). This information may influence an investigator's perception of a patient's willingness to participate in a sleep disorder treatment trial and may potentially influence clinical Trialists' decisions regarding the patients they select for inclusion in a clinical trial." - Anonymous Online Contributor
"Although it is used in a broad range of conditions, including rheumatoid arthritis and osteoarthritis, this review showed no evidence for any benefit of L-α lipoic acid 600 mg for controlling the pain or improving the function, mobility, or comfort in these conditions. This review also found no evidence to support it being useful in patients with rheumatoid arthritis associated with osteoarthritis." - Anonymous Online Contributor